Skip to main content
Journal cover image

Molecular biologic substaging of stage I lung cancer according to gender and histology.

Publication ,  Journal Article
D'Amico, TA; Aloia, TA; Moore, MB; Herndon, JE; Brooks, KR; Lau, CL; Harpole, DH
Published in: Ann Thorac Surg
March 2000

BACKGROUND: This study is designed to assess molecular biologic substaging according to gender and histology in patients with stage I non-small cell lung cancer (NSCLC). METHODS: Pathologic specimens were collected from 408 consecutive patients after complete resection for stage I NSCLC, with follow-up of at least 5 years. A panel of nine molecular markers was chosen for immunohistochemical analysis of the tumor: recessive oncogenes p53 and bcl-2, the protooncogene erbB-2, KI-67 proliferation index, retinoblastoma oncogene (Rb), epidermal growth factor receptor (EGFr), angiogenesis factor viii, sialyl-Tn antigen (STN), and CD-44. Cox proportional hazards regression analysis was used to construct a risk model for cancer-specific survival according to marker status, gender, and histologic subtype. RESULTS: Among men, the only molecular marker associated with decreased cancer-specific survival is erbB-2; among women, there are four markers: p53, Rb, CD-44, and factor viii. Among patients with squamous cell carcinoma, the only molecular marker associated with decreased cancer-specific survival is erbB-2; among patients with adenocarcinoma (AC), there are three markers: p53, CD-44, and factor viii. Multivariable analysis of interactions among molecular markers, gender, and histology demonstrates two important relationships (hazard ratio): p53+/women (2.269) and CD-44+/AC (2.266). CONCLUSIONS: Molecular biologic substaging of patients with stage I NSCLC demonstrates differential cancer-specific survival according to marker expression, gender, and histologic subtype.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Thorac Surg

DOI

ISSN

0003-4975

Publication Date

March 2000

Volume

69

Issue

3

Start / End Page

882 / 886

Location

Netherlands

Related Subject Headings

  • Survival Rate
  • Sex Factors
  • Risk Factors
  • Respiratory System
  • Neoplasm Staging
  • Molecular Biology
  • Male
  • Lung Neoplasms
  • Humans
  • Genetic Markers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
D’Amico, T. A., Aloia, T. A., Moore, M. B., Herndon, J. E., Brooks, K. R., Lau, C. L., & Harpole, D. H. (2000). Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg, 69(3), 882–886. https://doi.org/10.1016/s0003-4975(99)01522-2
D’Amico, T. A., T. A. Aloia, M. B. Moore, J. E. Herndon, K. R. Brooks, C. L. Lau, and D. H. Harpole. “Molecular biologic substaging of stage I lung cancer according to gender and histology.Ann Thorac Surg 69, no. 3 (March 2000): 882–86. https://doi.org/10.1016/s0003-4975(99)01522-2.
D’Amico TA, Aloia TA, Moore MB, Herndon JE, Brooks KR, Lau CL, et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000 Mar;69(3):882–6.
D’Amico, T. A., et al. “Molecular biologic substaging of stage I lung cancer according to gender and histology.Ann Thorac Surg, vol. 69, no. 3, Mar. 2000, pp. 882–86. Pubmed, doi:10.1016/s0003-4975(99)01522-2.
D’Amico TA, Aloia TA, Moore MB, Herndon JE, Brooks KR, Lau CL, Harpole DH. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000 Mar;69(3):882–886.
Journal cover image

Published In

Ann Thorac Surg

DOI

ISSN

0003-4975

Publication Date

March 2000

Volume

69

Issue

3

Start / End Page

882 / 886

Location

Netherlands

Related Subject Headings

  • Survival Rate
  • Sex Factors
  • Risk Factors
  • Respiratory System
  • Neoplasm Staging
  • Molecular Biology
  • Male
  • Lung Neoplasms
  • Humans
  • Genetic Markers